Halda Therapeutics
Aiyana Ward has a diverse work experience. In 2016, they worked as a Camp Counselor for the City of Waterbury, where they supervised and coordinated activities for children in grades 1-7. From 2018 to 2020, they worked as Event Staff at Eastern Connecticut State University. In 2020, they became a Student Intern at the City of Waterbury Health Department, and also took on the role of Office Assistant at Eastern Connecticut State University. Aiyana continued working at the City of Waterbury Health Department as a Contact Tracer until June 2022. In 2021, Aiyana was a Summer Research Intern at the Bill & Melinda Gates Medical Research Institute. In 2022, they worked as a Summer Intern at Arvinas. Currently, they are a Research Associate at Halda Therapeutics, starting in June 2023. Aiyana has gained valuable skills in research, organization, communication, leadership, and multitasking throughout their work experiences.
Aiyana Ward completed their undergraduate education from 2018 to 2022 at Eastern Connecticut State University. Aiyana pursued a degree in Biological Sciences with a specialization in Clinical/Medical Laboratory Science/Research and Allied Professions. Following their graduation, they joined the University of Miami in 2022 to pursue a Master of Science (MS) degree in Biological and Biomedical Sciences. The end year for their current program is not provided.
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.